GSK Net Profit Expected to Rise, Turnover to Fall -- Earnings Preview
BofA Securities Maintains GlaxoSmithKline(GSK.US) With Sell Rating
Analysts Offer Insights on Healthcare Companies: Insmed (INSM), GlaxoSmithKline (GSK) and Amylyx Pharmaceuticals Inc (AMLX)
Moderna's Stock-Price Target Slashed. It's About Vaccines. -- Barrons.com
Moderna Stock Price Target Slashed. It's About Vaccines. -- Barrons.com
IDEAYA Biosciences Reveals Clearance Of Investigational New DrugApplication With FDA For Initiation Of Phase 1 Clinical Trial To Evaluate Werner Helicase Development Candidate IDE275
It's Time to Get Your Covid and Flu Shots. Everything to Know About This Year's Vaccines. -- Barrons.com
GSK Stays in Red for Seven Straight Sessions
GlaxoSmithKline (GSK) Gets a Sell From J.P. Morgan
Graham Parry Recommends Sell Rating for GlaxoSmithKline Due to Concerns Over Arexvy Vaccine Efficacy and Safety
Earnings Preview: GSK to Report Financial Results Pre-market on October 30
$GlaxoSmithKline(GSK.US)$ is scheduled to release its financial results pre-market on October 30 ET. Earnings PreviewAnalysts estimate $GlaxoSmithKline(GSK.US)$ to post revenue of GBP8.07B for 2024Q3,
Unusual Options Activity: WYNN, RJF and Others Attract Market Bets, WYNN V/OI Ratio Reaches 377.5
EST Oct 24th Closing Delivery - In the last three hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options
Just After Pfizer's RSV Vaccine Approval For Younger Adults, GSK Layouts Encouraging Preliminary Data Showing Potential For Use In Larger Population
GSK to Invest Up to $800 Million to Expand Manufacturing Facility in Pennsylvania
CDC Issues Report On Missouri H5N1 Serology Testing; Confirms No Human-To-Human Transmission Of H5 Bird Flu Detected In US
GSK Reports Fresh Data to Support Expanded Indication for Arexvy
New Data for Arexvy, GSK's Respiratory Syncytial Virus Vaccine, Show Potential to Help Protect a Broader Group of Adults at Increased Risk for RSV Disease
FDA Approves Pfizer's Respiratory Syncytial Virus Vaccine Abrysvo For Adults Below 60 Years
Unusual Options Activity: TEVA, MRVL and Others Attract Market Bets, TEVA V/OI Ratio Reaches 1692.3
EST Oct 23rd Morning Delivery - In the last two hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends.
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields